The Consumer Staples Select Sector SPDR Fund (XLP)
- Previous Close
78.35 - Open
78.55 - Bid 78.09 x 1000
- Ask 78.18 x 29200
- Day's Range
77.96 - 78.65 - 52 Week Range
65.18 - 79.15 - Volume
11,815,537 - Avg. Volume
10,855,609 - Net Assets 15.63B
- NAV 78.38
- PE Ratio (TTM) 26.62
- Yield 2.82%
- YTD Daily Total Return 10.94%
- Beta (5Y Monthly) 0.58
- Expense Ratio (net) 0.09%
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
SPDR State Street Global Advisors
Fund Family
Consumer Defensive
Fund Category
15.63B
Net Assets
1998-12-16
Inception Date
Performance Overview: XLP
View MoreTrailing returns as of 7/17/2024. Category is Consumer Defensive.
People Also Watch
Holdings: XLP
View MoreTop 10 Holdings (71.83% of Total Assets)
Sector Weightings
Recent News: XLP
View More
Research Reports: XLP
View MoreMorningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, online commerce set for acceleration, consolidation; the market may be missing changes afoot at Veolia; an overview of the moat ratings for big biotech firms; and Kraft Heinz, Tyson Foods, and Nutrien.
Biogen: Lowering Our Moat Rating to Narrow Based on MS Sales Pressure and Leqembi Uncertainty
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
RatingPrice TargetTSMC: USD 6.6 Billion in Chips Act Grant Is a Slight Positive
Taiwan Semiconductor Manufacturing Co. is the world's largest dedicated chip foundry, with almost 60% market share. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the U.S. in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD, and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs. TSMC employs more than 73,000 people.
RatingPrice TargetMeta Earnings: Wide-Moat Meta Surpassed Expectations Again, but the Shares Are Overvalued
Meta is the world’s largest online social network, with nearly 4 billion family of apps monthly active users. Users engage with each other in different ways, exchanging messages and sharing news events, photos, and videos. The firm’s ecosystem consists mainly of the Facebook app, Instagram, Messenger, WhatsApp, and many features surrounding these products. Users can access Facebook on mobile devices and desktops. Advertising revenue represents more than 90% of the firm’s total revenue, with more than 45% coming from the U.S. and Canada and over 20% from Europe.
RatingPrice Target